NEW YORK, March 23, 2017 /PRNewswire/ --
Pre-market today, Stock-Callers.com has issued research reports on Mylan
On Wednesday, shares in UK-based Mylan N.V. rose 0.07%, ending the day at $41.70 with a volume of 4.36 million shares traded. The Company's shares have advanced 11.23% over the previous three months and 9.31% since the start of this year. The stock is trading above its 50-day and 200-day moving averages by 3.41% and 1.59%, respectively. Moreover, shares of Mylan, which together with its subsidiaries, develops, licenses, manufactures, markets, and distributes generic, brand name, and over-the-counter products worldwide, have an RSI of 48.96.
On March 13th, 2017, Mylan announced the US launch of Exemestane Tablets, 25 mg, a generic version of the reference listed drug, Pfizer's Aromasin® Tablets. Mylan received final approval from the US Food and Drug Administration (FDA) for its Abbreviated New Drug Application for this product, which is indicated in the treatment of certain types of breast cancer in women after menopause.
On March 13th, 2017, research firm Mizuho reiterated its 'Buy' rating on the Company's stock with an increase of the target price from $47 a share to $53 a share. MYL complete research report is just a click away and free at:
Shares in Ireland headquartered Allergan PLC ended the day 0.24% lower at $233.99 with a total trading volume of 2.23 million shares. In the previous three months and since the start of this year, the stock has gained 21.87% and 11.74%, respectively. The Company's shares are trading above their 50-day and 200-day moving averages by 0.52% and 2.63%, respectively. Furthermore, shares of Allergan, which develops, manufactures, markets, and distributes medical aesthetics, biosimilar, and over-the-counter pharmaceutical products worldwide, have an RSI of 41.38.
On March 22nd, 2017, Allergan announced the availability of RESTASIS MULTIDOSE™, which is the same preservative-free RESTASIS® formulation, but now offered in a multidose bottle. RESTASIS MultiDose™ is the first and only FDA-approved preservative-free, prescription eye drop in the US to be available in a multidose bottle. The complimentary report on AGN can be downloaded at:
At the close of trading on Wednesday, shares in Ireland headquartered Horizon Pharma PLC finished 0.21% higher at $14.52. A total volume of 3.35 million shares was traded, which was above their three months average volume of 2.71 million shares. The stock is trading below its 50-day moving average by 11.22%. Additionally, shares of Horizon Pharma, which engages in identifying, developing, acquiring, and commercializing medicines for the treatment of orphan diseases, arthritis, pain, and inflammation and inflammatory diseases, have an RSI of 33.23.
On March 16th, 2017, Horizon Pharma announced the launch of UCD in Common, an initiative for people impacted by a urea cycle disorder, a rare genetic disease characterized by toxic levels of ammonia in the blood. UCD in Common offers supportive, educational and interactive resources, and was created in collaboration with people living with UCD, their families, caregivers and healthcare professionals.
On February 28th, 2017, research firm Mizuho reiterated its 'Buy' rating on the Company's stock with a decrease of the target price from $25 a share to $22 a share. Sign up for your complimentary research report on HZNP at:
California headquartered Evoke Pharma Inc.'s shares recorded a trading volume of 424,032 shares at the end of yesterday's session. The stock closed the day 3.08% lower at $2.83. The Company's shares have surged 41.50% in the last three months and 40.10% on an YTD basis. The stock is trading below its 50-day moving average by 0.47%. Additionally, shares of Evoke Pharma, which focuses on the development of drugs for the treatment of gastroenterological disorders and diseases, have an RSI of 43.09.
On March 21st, 2017, Evoke Pharma announced that the Company's abstract detailing compelling Phase-3 trial data for Gimoti™ (metoclopramide nasal spray) for the relief of symptoms associated with acute and recurrent diabetic gastroparesis in women, was accepted for a poster presentation, which is titled Symptom Severity Influences Drug Efficacy in Women with Diabetic Gastroparesis: Results of a Phase-3 Study with Metoclopramide Nasal Spray, at Digestive Disease Week® 2017.
On March 16th, research firm Rodman & Renshaw reiterated its 'Buy' rating on the Company's stock with an increase of the target price from $6 a share to $9 a share. Get free access to your research report on EVOK at:
Stock Callers (SC) produces regular sponsored and non-sponsored reports, articles, stock market blogs, and popular investment newsletters covering equities listed on NYSE and NASDAQ and micro-cap stocks. SC has two distinct and independent departments. One department produces non-sponsored analyst certified content generally in the form of press releases, articles and reports covering equities listed on NYSE and NASDAQ and the other produces sponsored content (in most cases not reviewed by a registered analyst), which typically consists of compensated investment newsletters, articles and reports covering listed stocks and micro-caps. Such sponsored content is outside the scope of procedures detailed below.
SC has not been compensated; directly or indirectly; for producing or publishing this document.
PRESS RELEASE PROCEDURES:
The non-sponsored content contained herein has been prepared by a writer (the "Author") and is fact checked and reviewed by a third party research service company (the "Reviewer") represented by a credentialed financial analyst [for further information on analyst credentials, please email [email protected]. Rohit Tuli, a CFA® charterholder (the "Sponsor"), provides necessary guidance in preparing the document templates. The Reviewer has reviewed and revised the content, as necessary, based on publicly available information which is believed to be reliable. Content is researched, written and reviewed on a reasonable-effort basis. The Reviewer has not performed any independent investigations or forensic audits to validate the information herein. The Reviewer has only independently reviewed the information provided by the Author according to the procedures outlined by SC. SC is not entitled to veto or interfere in the application of such procedures by the third-party research service company to the articles, documents or reports, as the case may be. Unless otherwise noted, any content outside of this document has no association with the Author or the Reviewer in any way.
SC, the Author, and the Reviewer are not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted whatsoever for any direct, indirect or consequential loss arising from the use of this document. SC, the Author, and the Reviewer expressly disclaim any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Additionally, SC, the Author, and the Reviewer do not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.
NOT AN OFFERING
This document is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed, and is to be used for informational purposes only. Please read all associated disclosures and disclaimers in full before investing. Neither SC nor any party affiliated with us is a registered investment adviser or broker-dealer with any agency or in any jurisdiction whatsoever. To download our report(s), read our disclosures, or for more information, visit
CONTACT For any questions, inquiries, or comments reach out to us directly. If you're a company we are covering and wish to no longer feature on our coverage list contact us via email and/or phone between 09:30 EDT to 16:00 EDT from Monday to Friday at: Email: [email protected] Phone number: +44-330-808-3765 Office Address: Clyde Offices, Second Floor, 48 West George Street, Glasgow, U.K. -G2 1BP
CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.
SOURCE Chelmsford Park SA
Subscribe to our Free Newsletters!
Breathing in unclean air due to increasing air pollution could cause kidney damage with resultant ...
Benign prostatic hyperplasia or enlarged prostate is a noncancerous condition observed in men above ...
Urinary retention is a condition where a person is unable to voluntarily empty the urinary bladder ...View All